Danuglipron

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameDanuglipron
Drug Alias NameDanuglipron tromethaminePF-06882961PF-06882961 tromethaminePF-06882961-82
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesPfizer LtdPfizer Investment Co Ltd
Active IndicationsOverweightObesity
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes MellitusRenal Insufficiency +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG